arrow
J

Julie Kanter

University of Alabama at Birmingham
H指数:38
被引数:7,026

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Gene Therapy for Sickle Cell Disease: Practice Recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy

镰状细胞病基因治疗:移植与细胞治疗学会和国际细胞与基因治疗学会的实践建议

2026-03-280
OAAI
Successful implementation of stroke risk screening for sickle cell anemia in the DISPLACE study: results of a cluster randomized trial

DISPLACE研究中镰状细胞贫血卒中风险筛查的成功实施:一项集群随机试验的结果

2025-11-260
OAAI
Self-Management for Youth Living with Sickle Cell Disease (SMYLS): A study protocol for a multisite randomized controlled trial testing a behavioral, mHealth app

青少年镰状细胞病患者自我管理研究(SMYLS):一项针对测试行为学、移动健康应用程序的多中心随机对照试验的研究方案

2025-10-010
PRE
Grandchildren of GRNDaD: Shifts in disease-modifying therapy at the adolescent transition in sickle cell disease

GRNDaD的孙辈:镰状细胞病青少年过渡期疾病修饰治疗的转变

2025-07-310
PRE
Association of Surgical Splenectomy and Venous Thromboembolism and Stroke in People with Sickle Cell Disease

脾切除与静脉血栓栓塞及卒中在镰状细胞病患者中的关联

BLOOD
IF23.1
2024-11-050
PRE
An Update on Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials for Sickle Cell Disease (SCD) and Analysis of Early Predictors of Response to Lovo-Cel

关于Lovotibeglogene Autotemcel(Lovo-cel)治疗镰状细胞病(SCD)的临床试验进展及对Lovo-cel反应的早期预测因子分析

BLOOD
IF23.1
2024-11-050
PRE
Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease: final results from the phase II SOLACE-adults study

crizanlizumab在镰状细胞病患者中的药代动力学,药效学,安全性和有效性: II期SOLACE-成人研究的最终结果

2024-11-031
OAAI